Who is sponsoring NCT03948828?

NCT03948828 is sponsored by Shenzhen People's Hospital.

What drugs are being tested in NCT03948828?

Interventions in NCT03948828: Autologous NK cell therapy, GnRHa combained with reverse addition therapy.

What condition does NCT03948828 study?

NCT03948828 studies NK Cell Mediated Immunity, Endometriosis.

Is NCT03948828 still recruiting?

NCT03948828 is currently status unknown. Last updated 14 May 2019.

Last reviewed 2019-05-14 · How we verify

NCT03948828

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of NK Cells in the Treatment of Severe Endometriosis

Status unknown Phase 1 Last updated 14 May 2019

What this trial tests

Phase 1 trial testing Autologous NK cell therapy in NK Cell Mediated Immunity in 60 participants. Status unknown.

Timeline

1 June 2019

Primary endpoint
31 May 2022

31 December 2022

Quick facts

Lead sponsor	Shenzhen People's Hospital
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 June 2019
Primary completion	31 May 2022
Estimated completion	31 December 2022
Sites	1 location across China

Drugs / interventions tested

Autologous NK cell therapy — full drug profile →
GnRHa combained with reverse addition therapy — full drug profile →

Conditions studied

NK Cell Mediated Immunity — all drugs for NK Cell Mediated Immunity →
Endometriosis — all drugs for Endometriosis →

Sponsor

Shenzhen People's Hospital

Who can join

Adults 18 to 45, female only, with NK Cell Mediated Immunity or Endometriosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Dysfunction of natural koller cells (NK cells) is an important factor in the development of endometriosis. NK cell therapy was applied to treat severe endometriosis, which is an exploration of the pathogenesis of this refractory disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Promises of Natural Killer Cell Therapy in Endometriosis.
Hoogstad-van Evert J, Paap R, Nap A, van der Molen R. · · 2022 · cited 25× · PMID 35628346 · DOI 10.3390/ijms23105539

Verify or expand the search:

Other Shenzhen People's Hospital trials

Trials by the same sponsor.

NCT07512050 — Oral Lactobacillus Reuteri for Skin Barrier Dysfunction in Obesity · NA · not yet recruiting
NCT07366255 — Safety and Efficacy of Tripalmitoleoylglycerol in the Treatment of Dermatitis · NA · completed
NCT07366229 — Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne · Phase 2 · recruiting
NCT07266532 — Topical Lactobacillus Crispatus for Skin Barrier Dysfunction in Obesity · NA · completed
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03948828 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shenzhen People's Hospital
Last refreshed: 14 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03948828.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing